LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: OMICS Group
Languages: English
Types: Article
Subjects:
Leukaemia is the most common childhood cancer, and whilst recent advances in therapy have improved survival, current treatments are still limited by their side effects. Thus, new therapies are urgently needed, this study investigated the effects of Falcarinol, a polyacetylene isolated from carrots (Daucus carota) in combination with chemotherapy agents, anti-cancer agents and other apoptosis inducers. Inhibition of cellular proliferation and induction of apoptosis were investigated in three human lymphoid Leukaemia cell lines. Cellular proliferation was determined via ATP quantification using the Cell Titer Glo assay. Induction of apoptosis was investigated using caspase 3 activity assay and confirmed by nuclear morphology using Hoechst 33342. The study demonstrated that CCRF-CEM cells failed to induce synergistic response with any of the investigated chemotherapies, but importantly no inhibition was observed either. Jurkat cells showed a significant synergistic induction of apoptosis following joint treatment with Falcarinol and a Death Receptor 5 agonist (DR5), whereas CCRF-CEM cells showed only an additive response. Conversely within MOLT-3 cells Falcarinol partially inhibited the induction of apoptosis by DR5 agonist although this failed to reach significance. However MOLT-3 cells demonstrated synergistic induction of apoptosis when Falcarinol was combined with either Bortezomib (proteosome inhibitor), or Sulforaphane (histone deacetylase inhibitor). Identification of interactions between natural bioactive compounds with anti-cancer drugs may provide new pathways to target cancerous cells. Furthermore, since some combinations enhance apoptosis but some inhibit apoptosis it may be important to consider these interactions for dietary advice during therapy.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • http://www.cancerresearchuk.org/cancer-info/cancerstats/type/ Leukaemia/a=5441.
    • Zaini RG, Brandt K, Clench MR, Le Maitre CL (2012) Effects of bioactive compounds from carrots (Daucus carota L.), polyacetylenes, betacarotene and lutein on human lymphoid leukaemia cells. Anticancer Agents Med Chem 12: 640-652.
    • Zaini R, Clench MR, Le Maitre CL (2011) Bioactive chemicals from carrot (Daucus carota) juice extracts for the treatment of leukemia. J Med Food 14: 1303-1312.
    • Vermeulen K, Van Bockstaele DR, Berneman ZN (2005) Apoptosis: mechanisms and relevance in cancer. Ann Hematol 84: 627-639.
    • Brady HJ (2003) Apoptosis and leukaemia. Br J Haematol 123: 577-585.
    • Marsden VS, Strasser A (2003) Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Annu Rev Immunol 21: 71-105.
    • 9. Adams JM (2003) Ways of dying: multiple pathways to apoptosis. Genes Dev 17: 2481-2495.
    • 10. Rastogi RP, Sinha R, Sinha RP (2010) Apoptosis: Molecular mechanisms and pathogenicity. EXCLI Journal 8:155-181.
    • 11. Fadeel B, Orrenius S (2005) Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 258: 479-517.
    • 12. Müller M, Strand S, Hug H, Heinemann EM, Walczak H, et al. (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99: 403-413.
    • 13. Zamble DB, Lippard SJ (1995) Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 20: 435-439.
    • 14. Cilenti L, Kyriazis GA, Soundarapandian MM, Stratico V, Yerkes A, et al.
    • (2005) Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am J Physiol Renal Physiol 288: F371-379.
    • 15. Harmers FP, Gispen WH, Neijt JP (1991) Neurotoxic side-effects of cisplatin. Eur J Cancer 27: 372-376.
    • 16. Abdel Moneim AE, Othman MS, Aref AM (2014) Azadirachta indica attenuates cisplatin-induced nephrotoxicity and oxidative stress. Biomed Res Int 2014: 647131.
    • 17. Perez RP (1998) Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542.
    • 18. Gonzalez VM, Fuertes MA, Alonso C, Perez JM (2001) Is cisplatininduced cell death always produced by apoptosis? Mol Pharmacol 59: 657-663.
    • Pinto AL, Lippard SJ (1985) Binding of the antitumor drug cisdiamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta 780: 167-180.
    • Chupin V, de Kroon AI, de Kruijff B (2004) Molecular architecture of nanocapsules, bilayer-enclosed solid particles of Cisplatin. J Am Chem Soc 126: 13816-13821.
    • Hainsworth JD, Johnson DH, Frazier SR, Greco FA (1990) Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer 26: 818-821.
    • Mascaux C1, Paesmans M, Berghmans T, Branle F, Lafitte JJ, et al. (2000) A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30: 23-36.
    • Montecucco A, Biamonti G (2007) Cellular response to etoposide treatment. Cancer Lett 252: 9-18.
    • Tanaka T, Halicka HD, Traganos F, Seiter K, Darzynkiewicz Z (2007) Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase. Cell Cycle 6: 371-376.
    • Baldwin EL, Osheroff N (2005) Etoposide, topoisomerase II and cancer.
    • Curr Med Chem Anticancer Agents 5: 363-372.
    • (2008) Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26: 5755-5760.
    • Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, et al. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343: 1750-1757.
    • Begleiter A, Mowat M, Israels LG, Johnston JB (1996) Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Leuk Lymphoma 23: 187-201.
    • Sampath D, Rao VA, Plunkett W (2003) Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 22: 9063-9074.
    • Yang L, Wu D, Luo K, Wu S, Wu P (2006) Andrographolide enhances 5- fluorouracil-induced apoptosis via caspase-8-dependent mitochondrial pathway involving p53 participation in hepatocellular carcinoma (SMMC-7721) cells. Cancer Lett 276: 180.
    • Zhang N, Yin Y, Xu SJ, Chen WS (2008) 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 13: 1551-1569.
    • Ceilley RI (2012) Mechanisms of action of topical 5-fluorouracil: review and implications for the treatment of dermatological disorders. J Dermatolog Treat 23: 83-89.
    • Podsiadlo P, Sinani VA, Bahng JH, Kam NW, Lee J, et al. (2008) Gold nanoparticles enhance the anti-leukemia action of a 6-mercaptopurine chemotherapeutic agent. Langmuir 24: 568-574.
    • Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE (1999) Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93: 2817-2823.
    • Kano Y, Akutsu M, Suzuki K, Yoshida M (1993) Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines.
    • Leuk Res 17: 113-119.
    • Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ (2003) Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171: 88-95.
    • (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076.
    • Griger Z, Tóth BI, Baráth S, Gyetvai A, Kovács I, et al. (2011) Different effects of Bortezomib on the expressions of various PKC isoenzymes in T cells of patients with systemic lupus erythematosus and in Jurkat cells.
    • Chen JF, Jin J (2009) [Apoptosis in Jurkat cells induced by bortezomib combined with adriamycin]. Zhonghua Zhong Liu Za Zhi 31: 890-893.
    • An J, Sun Y, Fisher M, Rettig MB (2004) Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 18: 1699-1704.
    • Nie D, Huang K, Yin S, Li Y, Xie S, et al. (2012) Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells. Leuk Lymphoma 53: 2487-2495.
    • Dai Y, Chen S, Wang L, Pei XY, Kramer LB, et al. (2011) Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. Br J Haematol 153: 222-235.
    • Liu FT, Agrawal SG, Movasaghi Z, Wyatt PB, Rehman IU, et al. (2008) Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood 112: 3835-3846.
    • (2008) Combined effects of p53 gene therapy and leptomycin B in human esophageal squamous cell carcinoma. Oncology 75: 113-119.
    • Jang BC, Paik JH, Jeong HY, Oh HJ, Park JW, et al. (2004) Leptomycin Binduced apoptosis is mediated through caspase activation and downregulation of Mcl-1 and XIAP expression, but not through the generation of ROS in U937 leukemia cells. Biochem Pharmacol 68: 263-274.
    • Aloisi A, Di Gregorio S, Stagno F, Guglielmo P, Mannino F, et al. (2006) BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.
    • Blood 107: 1591-1598.
    • Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH (2006) Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J 20: 506-508.
    • (2009) Sulforaphane targets pancreatic tumour-initiating cells by NFkappaB-induced antiapoptotic signalling. Gut 58: 949-963.
    • Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, et al. (2010) Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 70: 5004-5013.
    • Guo Y, Chen C, Zheng Y, Zhang J, Tao X, et al. (2005) A novel antihuman DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem 280: 41940-41952.
    • Wudtiwai B, Sripanidkulchai B, Kongtawelert P, Banjerdpongchai R (2011) Methoxyflavone derivatives modulate the effect of TRAILinduced apoptosis in human leukemic cell lines. J Hematol Oncol 4: 52.
    • Kwa FA, Cole-Sinclair M, Kapuscinski M (2010) Chlorambucil-sensitive and-resistant lymphoid cells display different responses to the histone deacetylase inhibitor, sodium butyrate. Biochem Biophys Res Commun; 403: 288-292.
    • Jordan A, Stein J (2003) Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2. Eur J Nutr 42: 324-331.
    • Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A (2009) TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 35: 280-288.
    • Wang J, Lin Z, Qiao CX, Lv M, Yu M, et al. (2008) Characterization of a novel anti-DR5 monoclonal antibody WD1 with the potential to induce tumor cell apoptosis. Cell Mol Immunol 5: 55-60.
    • Almasan A, Ashkenazi A (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14: 337-348.
    • Du YW, Chen JG, Bai HL, Huang HY, Wnag J, et al. (2011) A Novel agonistic anti-human death receptor 5 monoclonal antibody with tumoricidal acticity induces caspase and mitochondrial dependant apoptosis in human leukemia Jurkat cells. Cancer Biother Radiopharm 26: 143-152.
    • Chen D, Chan R, Waxman S, Jing Y (2006) Buthionine Sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2 terminal Kinase and Up regulation of death receptors. Cancer Res 66: 11416-11423.
    • 59. Jang BC, Muñoz-Najar U, Paik JH, Claffey K, Yoshida M, et al. (2003) Leptomycin B, an inhibitor of the nuclear export receptor CRM1, inhibits COX-2 expression. J Biol Chem 278: 2773-2776.
    • 60. Choi WY, Choi BT, Lee WH, Choi YH (2008) Sulforaphane generates reactive oxygen species leading to mitochondrial perturbation for apoptosis in human leukemia U937 cells. Biomedicine & Pharmacotherapy 62: 637-644.
    • 61. Fimognari C, Lenzi M, Sciuscio D, Cantelli-Forti G, Hrelia P (2007) Cellcycle specificity of sulforaphane-mediated apoptosis in Jurkat T-leukemia cells. In Vivo 21: 377-380.
    • 62. Purup S, Larsen E, Christensen LP (2009) Differential effects of falcarinol and related aliphatic C(17)-polyacetylenes on intestinal cell proliferation.
    • J Agric Food Chem 57: 8290-8296.
    • 63. Yan Z, Yang R, Jiang Y, Yang Z, Yang J, et al. (2011) Induction of apoptosis in human promyelocytic leukemia HL60 cells by panaxynol and panaxydol. Molecules 16: 5561-5573.
    • 64. Shawgo ME, Shelton SN, Robertson JD (2009) Caspase-9 activation by the apoptosome is not required for fas-mediated apoptosis in type II Jurkat cells. J Biol Chem 284: 33447-33455.
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article